×
About 520 results

ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  155 results

Real-world data with the use of caplacizumab in the treatment of acquired thrombotic th...
https://doi.org/10.1111/trf.17111
Transfusion Jiménez M, Bobillo S et. al.

Sep 25th, 2022 - Recently, real-world data confirmed the effectiveness of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP); however, limitations as different treatment protocols from multicenter experiences and the front-line us...

Semi-selective plasma filtration applied to the treatment of acquired thrombotic thromb...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440330
Journal of Nephrology; Fenoglio R, Marchisio M et. al.

Sep 4th, 2022 - Following the widespread use of anti SARS-CoV-2 vaccines, there have been reports of thrombocytopenia developing after the administration of different types of vaccine. We report a case of a 63-year-old male who developed neurological symptoms aft...

Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus ery...
https://doi.org/10.1007/s00296-022-05182-5
Rheumatology International; Mutoh T, Ohashi K et. al.

Aug 13th, 2022 - Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of various autoantibodies and deposition of immune complexes on tissues. Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening hematolog...

Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibito...
https://doi.org/10.1016/j.intimp.2022.109015
International Immunopharmacology; Moore DC, Elmes JB et. al.

Jul 9th, 2022 - Immune checkpoint inhibitors (ICIs) are used for a variety of cancers and are associated with a risk of developing immune-related adverse events, most commonly colitis, dermatitis, hepatitis, and thyroiditis. Rare autoimmune hematologic toxicities...

Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Va...
https://doi.org/10.1055/s-0042-1744301
Seminars in Thrombosis and Hemostasis; Tso ACY, Ong KH et. al.

Jun 28th, 2022 - Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Vaccine?|2022|Tso ACY,Ong KH,Sum CLL,Fan BE,Chan GYL,|

see more →

Drugs  3 results see all →

Clinicaltrials.gov  7 results

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
https://clinicaltrials.gov/ct2/show/NCT04074187

Apr 25th, 2022 - Study duration per participant is approximately 2 months up to approximately 6 months in case of treatment extension and recurrence during the study drug treatment period.

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
https://clinicaltrials.gov/ct2/show/NCT02878603

Mar 28th, 2022 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
https://clinicaltrials.gov/ct2/show/NCT05262881

Mar 2nd, 2022 - This study is a multicenter, retrospective, observational study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) treated with plasma exchange (PEX) in association with caplacizumab, and immunosuppression between Q4-2019 and 28 ...

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
https://clinicaltrials.gov/ct2/show/NCT03922308

Feb 21st, 2022 - The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
https://clinicaltrials.gov/ct2/show/NCT04021173

Jul 17th, 2019 - The study will consist of 3 periods: screening(up to 7 days), treatment and follow-up(up to 3 months). Subjects are assigned in a 1:1 ratio to Anfibatide or placebo during plasma exchange with the use of a computerized randomization schedule. The ...

see more →

News  43 results

Real-world outcomes of caplacizumab for iTTP comparable to clinical trial results
https://www.mdedge.com/hematology-oncology/article/238288/bleeding-disorders/real-world-outcomes-caplacizumab-ittp
Mark S. Lesney, PhD

Apr 7th, 2021 - Real-world data for caplacizumab outcomes matched those seen in randomized controlled trials (RCTs) for the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to the results of a retrospective study. Data collected.

FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
https://www.onclive.com/view/fda-approvals-in-myeloma-and-attp-priority-review-designations-in-rcc-and-hnscc-and-more

Apr 2nd, 2021 - Today- FDA approvals in multiple myeloma and acquired thrombotic thrombocytopenic purpura, priority review designations in renal cell carcinoma and head and neck squamous cell carcinoma, an ODAC meeting scheduled in multiple myeloma, and a revi...

New Agents Abound in Benign Hematologic Disorders
https://www.onclive.com/view/new-agents-abound-in-benign-hematologic-disorders

Dec 20th, 2020 - Kleber Yotsumoto Fertrin, MD, PhD With the emergence of new agents in benign hematologic disorders and more in the pipeline, the outlook for patients with aplastic anemia, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TT...

Cost is the main hurdle to broad use of caplacizumab for TTP
https://www.mdedge.com/hematology-oncology/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
M. Alexander Otto

Dec 7th, 2020 - As hematologists debated the role of the anti–von Willebrand factor agent caplacizumab for acquired thrombotic thrombocytopenic purpura (TTP), an investigator on the phase 3 trial that led to its approval had a message. “If we take finances out” o.

FDA Approvals Boost Competition in Treatment Landscapes
https://www.onclive.com/view/fda-approvals-boost-competition-in-treatment-landscapes

Dec 5th, 2020 - Therapeutic developments in cancer were rewarded with a wave of approvals in 2019. Tumor types such as breast cancer and prostate cancer saw multiple approvals, while continued research offered more targeted therapies across cancer types. May was ...

see more →